AstraZeneca to use part of Russian COVID-19 vaccine in trials

Pharmaceutical giant AstraZeneca's Russian branch said Friday it would use part of Russia's homemade Sputnik V vaccine in further clinical trials. 

"Today we announce a clinical trial program to assess safety and immunogenicity of a combination of AZD1222, developed by AstraZeneca and Oxford University, and Sputnik V, developed by Russian Gamaleya Research institute" AstraZeneca said in a statement published on its website in English and Russian. -Agence France-Presse